What You Need to Know About Biogen Inc.'s Q3 Earnings
Biogen Inc.'s fiscal Q3 earnings report was released on Wednesday, July 29. Let's dive in to see if (BIIB) missed or beat analyst's expectations.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer’s disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Is Biogen Inc. (BIIB) Overvalued?
We dive into why Biogen Inc. (BIIB) could be considered overvalued on 2026-07-17, based on AAII’s Value Score and Grade.Tudor Pop
Why Biogen Inc.’s (BIIB) Stock Is Down 7.67%
As of Tuesday, July 14, Biogen Inc.’s BIIB share price has dipped by 7.67%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Biogen Inc.’s (BIIB) Stock Is Up 6.06%
As of Friday, June 26, Biogen Inc.’s BIIB share price has surged by 6.06%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Which Is a Better Investment, Amgen Inc. or Biogen Inc. Stock?
Learn more about whether Amgen Inc. or Biogen Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Financial Summary
| Share Statistics | BIIB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $30,722.5 | $251.9 | 90% |
|
| Shares Out (Mil) | 148.7 | 50.8 | 71% |
|
| Institutional Ownership | 99.8% | 92.0% | 94% |
|
| Float (Mil) | 147.3 | 40.5 | 69% |
|
| Beta | 0.16 | 0.95 | 11% |
|
| Avg Daily Volume (000s) | 1,112 | 447 | 73% |
|
| Price Change (52-week) |
62.6% | 54.2% | 85% |
|
| Growth | BIIB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (6.0%) | 14.0% | 8% |
|
| Net Income (5yr) | (20.2%) | (9.8%) | 20% |
|
| EPS (5yr) | (18.7%) | 16.3% | 14 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 19.5% | (15.6%) | 79% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 22 | 23 | 30 | |
| Current EPS | $2.181 | $12.457 | $16.576 | |
| Month Ago EPS | $3.935 | $13.325 | $16.625 | |
| # Rev Up | 1 | 6 | 2 | |
| # Rev Down | 0 | 19 | 1 | |
| Three Months Ago EPS | $3.984 | $13.455 | $16.433 | |
| Year/Year Chg | 230.5% | 41.7% | 113.3% | |
| Financials | BIIB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $10,028 | $39 | 84% |
|
| Net Income (TTM) (Mil) | $835 | ($43) | 84% |
|
| EPS (TTM) | $5.676 | ($1.600) | 88% |
|
| Operating Cash Flow (TTM) (Mil) | $2,879 | ($30) | 91% |
|
| Net Cash Flow (TTM) (Mil) | ($1,474) | $3 | 2% |
|
| Long-Term Debt (Q1) (Mil) | $7,555 | $5 | 89% |
|
| Enterprise Value (Q1) (Mil) | $37,960 | $182 | 90% |
|
| Valuation | BIIB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.63 | 2.60 | 43% |
|
| P/E | 36.9 | 18.6 | 76% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | BIIB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.6% | 63.8% | 87% |
|
| Net Margin | 8.3% | (64.7%) | 59% |
|
| ROA | 2.8% | (49.7%) | 61% |
|
| ROE | 4.6% | (55.4%) | 43% |
|
| Liabilities to Assets | 41.3% | 30.3% | 32% |
|
| F-Score | 4 | 3 | 34% |
|
Biogen Inc. did not pass any screens on 7/30/2026.
